vs
慧与（EFSC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是慧与的1.1倍（$207.3M vs $185.2M），慧与净利率更高（26.6% vs -62.0%，领先88.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.0%）
慧与（Hewlett Packard Enterprise，简称HPE）是总部位于美国得克萨斯州斯普林的跨国信息技术企业，面向企业客户提供服务器、存储、网络、容器化软件及咨询支持服务，2018年位列美国《财富》500强第107位。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EFSC vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$185.2M
净利率更高
EFSC
高出88.7%
-62.0%
两年增速更快
RARE
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.2M | $207.3M |
| 净利润 | $49.4M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 26.6% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | -1.2% | 3.5% |
| 每股收益（稀释后） | $1.30 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EFSCRARE
| Q1 26 | $185.2M | — | ||
| Q4 25 | $193.6M | $207.3M | ||
| Q3 25 | $206.9M | $159.9M | ||
| Q2 25 | $173.4M | $166.5M | ||
| Q1 25 | $166.0M | $139.3M | ||
| Q4 24 | $167.0M | $164.6M | ||
| Q3 24 | $164.9M | $139.5M | ||
| Q2 24 | $156.0M | $147.0M |
净利润EFSCRARE
| Q1 26 | $49.4M | — | ||
| Q4 25 | $54.8M | $-128.6M | ||
| Q3 25 | $45.2M | $-180.4M | ||
| Q2 25 | $51.4M | $-115.0M | ||
| Q1 25 | $50.0M | $-151.1M | ||
| Q4 24 | $48.8M | $-133.2M | ||
| Q3 24 | $50.6M | $-133.5M | ||
| Q2 24 | $45.4M | $-131.6M |
营业利润率EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | 42.9% | -106.9% | ||
| Q2 25 | 37.0% | -64.8% | ||
| Q1 25 | 36.8% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 38.1% | -94.6% | ||
| Q2 24 | 36.7% | -79.1% |
净利率EFSCRARE
| Q1 26 | 26.6% | — | ||
| Q4 25 | 28.3% | -62.0% | ||
| Q3 25 | 21.9% | -112.8% | ||
| Q2 25 | 29.6% | -69.0% | ||
| Q1 25 | 30.1% | -108.5% | ||
| Q4 24 | 29.2% | -80.9% | ||
| Q3 24 | 30.7% | -95.7% | ||
| Q2 24 | 29.1% | -89.5% |
每股收益（稀释后）EFSCRARE
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.45 | $-1.28 | ||
| Q3 25 | $1.19 | $-1.81 | ||
| Q2 25 | $1.36 | $-1.17 | ||
| Q1 25 | $1.31 | $-1.57 | ||
| Q4 24 | $1.27 | $-1.34 | ||
| Q3 24 | $1.32 | $-1.40 | ||
| Q2 24 | $1.19 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $-80.0M |
| 总资产 | $17.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
股东权益EFSCRARE
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $-80.0M | ||
| Q3 25 | $2.0B | $9.2M | ||
| Q2 25 | $1.9B | $151.3M | ||
| Q1 25 | $1.9B | $144.2M | ||
| Q4 24 | $1.8B | $255.0M | ||
| Q3 24 | $1.8B | $346.8M | ||
| Q2 24 | $1.8B | $432.4M |
总资产EFSCRARE
| Q1 26 | $17.3B | — | ||
| Q4 25 | $17.3B | $1.5B | ||
| Q3 25 | $16.4B | $1.2B | ||
| Q2 25 | $16.1B | $1.3B | ||
| Q1 25 | $15.7B | $1.3B | ||
| Q4 24 | $15.6B | $1.5B | ||
| Q3 24 | $15.0B | $1.5B | ||
| Q2 24 | $14.6B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | $193.5M | $-99.8M | ||
| Q3 25 | $49.4M | $-91.4M | ||
| Q2 25 | $61.3M | $-108.3M | ||
| Q1 25 | $40.0M | $-166.5M | ||
| Q4 24 | $247.4M | $-79.3M | ||
| Q3 24 | $89.0M | $-67.0M | ||
| Q2 24 | $76.5M | $-77.0M |
自由现金流EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | $181.5M | $-100.8M | ||
| Q3 25 | $47.1M | $-92.7M | ||
| Q2 25 | $59.0M | $-110.7M | ||
| Q1 25 | $35.6M | $-167.8M | ||
| Q4 24 | $239.9M | $-79.5M | ||
| Q3 24 | $88.2M | $-68.6M | ||
| Q2 24 | $74.7M | $-79.0M |
自由现金流率EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | 93.8% | -48.6% | ||
| Q3 25 | 22.8% | -58.0% | ||
| Q2 25 | 34.0% | -66.5% | ||
| Q1 25 | 21.5% | -120.5% | ||
| Q4 24 | 143.7% | -48.3% | ||
| Q3 24 | 53.5% | -49.2% | ||
| Q2 24 | 47.9% | -53.7% |
资本支出强度EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 0.5% | ||
| Q3 25 | 1.1% | 0.8% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 2.7% | 1.0% | ||
| Q4 24 | 4.5% | 0.1% | ||
| Q3 24 | 0.5% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% |
现金转化率EFSCRARE
| Q1 26 | — | — | ||
| Q4 25 | 3.53× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 5.07× | — | ||
| Q3 24 | 1.76× | — | ||
| Q2 24 | 1.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EFSC
| Net Interest Income | $166.1M | 90% |
| Noninterest Income | $19.1M | 10% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
